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Abstract
Background: Healthy life expectancy – sometimes called health-adjusted life expectancy (HALE)
– is a form of health expectancy indicator that extends measures of life expectancy to account for
the distribution of health states in the population. The World Health Organization reports on
healthy life expectancy for 192 WHO Member States. This paper describes variation in average
levels of population health across these countries and by sex for the year 2002.
Methods: Mortality was analysed for 192 countries and disability from 135 causes assessed for 17
regions of the world. Health surveys in 61 countries were analyzed using new methods to improve
the comparability of self-report data.
Results: Healthy life expectancy at birth ranged from 40 years for males in Africa to over 70 years
for females in developed countries in 2002. The equivalent "lost" healthy years ranged from 15% of
total life expectancy at birth in Africa to 8–9% in developed countries.
Conclusion: People living in poor countries not only face lower life expectancies than those in
richer countries but also live a higher proportion of their lives in poor health.
Background
In the World Health Report 2000, the World Health Organ-
ization (WHO) reported for the first time on the average
levels of population health for its 191 member countries
using a summary measure that combines information on
mortality and morbidity [1,2]. Because substantial
resources are devoted to reducing the incidence of condi-
tions that cause ill-health but not death and to reducing
their impact on people's lives, it is important to capture
both fatal and non-fatal health outcomes in any such
measure of population health. Healthy life expectancy –
sometimes called health-adjusted life expectancy (HALE)
– is a form of health expectancy indicator that extends
measures of life expectancy to represent the average health
in a population in terms of equivalent years of full health,
taking into account the distribution of health states [3].
HALE has been calculated previously for Canada and Aus-
tralia using population survey data on disability [4-6]. The
United States has adopted a public health policy goal to
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increase the expected years of healthy life in the popula-
tion and has used a type of healthy life expectancy to
measure progress towards this goal [7,8]. In calculating
HALE for 191 WHO Member States for 1999, we carried
out an analysis of 62 representative population health sur-
veys which revealed substantial problems with compara-
bility of self-report health status and disability data [2].
We used health state prevalence estimates from the Global
Burden of Disease 2000 project to adjust for biases in self-
report data; the independent information on levels of
population health provided by the health surveys was
thus quite limited.
It has long been known that health expectancy estimates
based on self-reported health status information are not
comparable across countries due to differences in survey
instruments and cultural differences in reporting of health
[9,10]. The International Network on Health Expectancy
(REVES) and international agencies have devoted sub-
stantial efforts to try to standardize questionnaire instru-
ments and methods [11-13]. Though some cross-national
surveys using a common self-report instrument have
become available [14], standardized instruments alone
do not solve comparability problems [15]. These relate
more fundamentally to unmeasured differences in expec-
tations and norms for health, so that the meaning differ-
ent populations attach to the labels used for response
categories in self-reported questions, such as mild, moder-
ate or severe, can vary greatly.
Given these problems, WHO undertook a Multi-Country
Survey Study on Health and Responsiveness (MCSS) in
2000 and 2001 in collaboration with Member States using
a standardized health status survey instrument together
with new statistical methods for adjusting biases in self-
reported health [16-19]. These new data, together with
comprehensive analyses of epidemiological data for all
regions of the world, and new life tables for all WHO
Member States, have enabled us to calculate HALE for 192
countries for 2002 in a way that improves comparability
across countries. These results are reported in the World
Health Report 2004 [20]. A previous paper has examined
variations in HALE among OECD countries [21]. This
paper examines the implications of the results for our
understanding of global patterns of health.
Methods
Calculation of HALE requires three inputs: life tables,
prevalences of various health states, and valuations of
time spent in these health states compared to full health.
The WHO methods used to calculate HALE have been
developed to maximise its comparability across popula-
tions. These methods are described in more detail else-
where [22,23] and have been reviewed by an independent
scientific peer review group [24]. A set of spreadsheet tools
are also under development to provide full access to the
inputs and calculations for country-specific HALE for
2002; these will enable users to modify inputs and to carry
out sensitivity analyses for various factors. This section
provides an overview of these methods and data sources
and a more detailed description of adjustments for insti-
tutionalized populations.
Life table methods
Procedures used to estimate the 2002 life tables differed
for Member States depending on the data availability to
assess child and adult mortality. Complete or incomplete
vital registration data together with sample registration
systems cover 72% of global mortality. Survey data and
indirect demographic techniques provide information on
levels of child and adult mortality for the remaining 28%
of estimated global mortality. Separate estimates were
used for the numbers and distributions of deaths due to
HIV/AIDS in countries with a substantial HIV epidemic
[25]. A full overview of methods used to construct life
tables is given elsewhere [20,26,27].
Following an initial scientific review [24], significant
improvements were implemented in both data and meth-
ods used to calculate life expectancies for WHO Member
States. Recent surveys and censuses provided substantially
more information on levels of child and adult mortality in
Member States lacking complete death registration. This
has resulted in changes in point estimates of life expectan-
cies and reductions in uncertainty ranges for some Mem-
ber States compared to previously published estimates.
Health state prevalence data
Because comparable health state prevalence data are not
yet available for all countries, two sources of information
were used: the Global Burden of Disease (GBD) study and
the MCSS. Data from the GBD study were used to estimate
severity-adjusted prevalences by age and sex for all 192
countries [23]. Secondly, data from the MCSS were used
to make independent estimates of severity-adjusted prev-
alences by age and sex for 55 countries. Finally, 'posterior'
prevalences for all countries were calculated based on the
GBD-based prevalences and the survey prevalences as
described below. This process is summarized in Figure 1.
The GBD revisions draw on a wide range of data sources
to develop internally consistent estimates of incidence,
prevalence, duration and years lived with disability
(YLD), for 135 major causes, for 14 sub-regions of the
world [20]. Prevalence-based YLD rates were calculated,
and adjusted for co-morbidity, giving direct estimates of
the severity-weighted prevalence of health states attribut-
able to each cause [23].BMC Public Health 2004, 4:66 http://www.biomedcentral.com/1471-2458/4/66
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Tables 1 and 2 summarize the major causes of YLD for
developed and developing countries in the year 2002 as
published in the World Health Report 2004 [20]. Neu-
ropsychiatric conditions accounted for 42% of YLD in
developed countries and nearly 30% of YLD in develop-
ing countries. Unipolar depression is the leading contrib-
utor to this burden. Other major causes of YLD include
vision and hearing loss (9% in developed countries and
13% in developing countries) and injuries (nearly 12% in
developing countries and 7% in developed countries).
More detailed estimates of YLD by age group and cause
are available for 14 subregions of the WHO Regions, and
for countries grouped into high, medium and low income
categories, on the WHO website at http://www.who.int/
evidence/bod.
Summation of prevalence YLD across all causes would
result in overestimation of the total average severity-
weighted health state prevalence because of comorbidity
between conditions. In earlier calculations of HALE,
adjustments were made for independent comorbidity
assuming that the probability of having two (comorbid)
conditions would equal the product of the probabilities
for having each of the diseases. For the World Health
Report 2003, further work was undertaken to take
dependent comorbidity into account more rigorously
[28]. For many diseases, the probability of having a pair of
diseases is greater than the product of the probabilities for
each disease, reflecting common causal pathways (for
example common risk factors causing both diabetes and
heart disease) and also that one disease may increase the
risk of another.
Estimation of severity-adjusted health state prevalences for calculation of HALE Figure 1
Estimation of severity-adjusted health state prevalences for calculation of HALE.
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Data from five large national health surveys were analysed
by age and sex to estimate "dependent comorbidity fac-
tors" for pairs of conditions. There was surprising consist-
ency in these factors across the five surveys and the results
were used for all Member States to adjust for dependent
comorbidity in summation of prevalence YLD across all
causes [28].
MCSS Survey estimates
The MCSS was carried out in 2000–2001. A total of 71 sur-
veys were completed in 61 countries using face-to-face,
postal and telephone interviewing modes [16]. Thirty-five
of the surveys were carried out in 31 Western and Eastern
European countries, 27 surveys in 22 developing coun-
tries, and the remainder in Canada, USA, Australia and
New Zealand. To overcome the problem of comparability
of self-report health data, the WHO survey instrument
used anchoring vignettes to calibrate self-reported health
for the 6 core health domains (mobility, self care, pain,
affect, work and household activities, cognition) and
vision. Anchoring vignettes are short descriptions that
mark fixed levels of ability (e.g. people with different lev-
els of mobility such as a paraplegic person or an athlete
who runs 4 km each day) and allow us to adjust for indi-
vidual variations in the use of response categories to
describe the same health state [17,18,29].
We included in the analysis only those surveys that have
met certain explicit criteria that reflect the quality of sur-
vey implementation with specific reference to the health
vignettes. The USA postal survey was also excluded
because respondents were presented the vignettes in order
of severity rather than randomized as in the case of all
other surveys. Sixty-two surveys met these criteria and
were included in the model. Health state prevalences from
the WHO Multi-country Household Survey Study were
assumed to relate to calendar year 2000. Trends in preva-
lence YLD between 2000 and 2002 were calculated for
each Member State using the GBD estimates. Aggregated
across all causes, these trends were generally small. In cal-
culating HALE for 2002, the 2000 survey results were
adjusted for likely change over two years using these esti-
mated trends.
Table 1: Leading causes of disability, years lived with disability (YLD) by cause as percent of YLD from all causes, developed countriesa, 
2002
Cause group % of total YLD Female to male ratio
I. Communicable, maternal, perinatal and nutritional conditions 6.6 1.47
Infectious and parasitic diseases 2.4 0.94
Maternal conditions 0.9 -
Perinatal conditions 0.8 0.95
Nutritional deficiencies 2.1 1.50
II. Noncommunicable diseases 86.2 1.12
Malignant neoplasms 2.4 1.54
Diabetes mellitus 2.3 1.10
Neuropsychiatric conditions 41.9 1.10
Unipolar depressive disorders 15.0 1.69
Bipolar disorder 2.2 0.99
Schizophrenia 2.3 0.94
Alcohol use disorders 6.8 0.24
Alzheimer and other dementias* 4.2 1.99
Drug use disorders 1.7 0.34
Other neuropsychiatric disorders 9.7 1.50
Sense organ diseases 8.6 1.16
Vision disordersb 3.0 1.44
Hearing loss, adult onset 5.7 1.04
Cardiovascular diseases 6.7 0.86
Respiratory diseases 6.9 0.96
Musculoskeletal diseases 7.6 1.53
Other non-communicable diseases 9.7 1.09
III. Injuries 7.2 0.45
Unintentional injuries 5.8 0.48
Intentional injuries 1.4 0.31
a Developed countries includes European countries, former Soviet countries, Canada, USA, Cuba, Japan, Australia, New Zealand, Brunei 
Darussalam, Singapore.
b Vision disorders includes vision loss due to glaucoma, cataracts, macular degeneration and other age-related vision loss.BMC Public Health 2004, 4:66 http://www.biomedcentral.com/1471-2458/4/66
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Health state valuations
The health state valuations used in HALE calculations rep-
resent average population assessments of the overall
health levels associated with different states. They range
from 0 representing a state of good or ideal health to 1
representing states equivalent to being dead. These
weights do not measure average levels of well-being or
quality of life associated with health states, or imply any
societal value of a person in a disability or health state.
Rather they characterize health decrements on a contin-
uum starting from the societal ideal of good health.
Household surveys including a valuation module were
conducted in fourteen countries: China, Colombia, Egypt,
Georgia, India, Iran, Lebanon, Indonesia, Mexico,
Nigeria, Singapore, Slovakia, Syria and Turkey. Data on
nearly 500,000 health state valuations from over 46,000
respondents were used to develop a mapping function
that captured the average relationships between levels on
the six core health domains and overall health state valu-
ations. This average global valuation function was then
applied to the vignette-adjusted health domain levels for
each survey respondent in order to estimate health state
valuations for the calculation of HALE [30,31].
The MCSS survey samples did not include older people
resident in nursing homes or other health institutions.
Because these people will generally have worse health
than those resident in households, adjustments were
made to account for the older population who were
resident in health institutions. Fifty-four national esti-
mates of the proportion of the population aged 65 years
and over who are resident in nursing homes were col-
lected for 36 countries from national statistical publica-
tions and international statistical databases of OECD and
the World Bank. These were used to estimate the
percentage of the population aged 60+ years institutional-
ized in MCSS countries. This ranged from 3 to 5% in most
OECD countries, was highest at around 7% in the Nether-
lands and Sweden, was substantially lower at around 0.3
to 1% in Eastern European countries, and was close to
zero for developing countries. As data on the severity dis-
tribution of health states in institutionalized populations
were not available, an average disability weight of 0.5
Table 2: Leading causes of disability, years lived with disability (YLD) by cause as percent of YLD from all causes, developing 
countriesa, 2002
Cause group % of total YLD Female to male ratio
I. Communicable, maternal, perinatal and nutritional conditions 23.4 1.36
Infectious and parasitic diseases 10.9 0.95
Maternal conditions 3.8 -
Perinatal conditions 3.1 0.98
Nutritional deficiencies 4.4 1.08
II. Noncommunicable diseases 64.9 1.03
Malignant neoplasms 0.3 2.02
Diabetes mellitus 1.1 1.11
Neuropsychiatric conditions 29.4 1.09
Unipolar depressive disorders 11.1 1.47
Bipolar disorder 2.5 0.98
Schizophrenia 2.9 0.97
Alcohol use disorders 2.5 0.15
Alzheimer and other dementias* 1.0 1.40
Drug use disorders 0.8 0.28
Other neuropsychiatric disorders 8.6 1.37
Sense organ diseases 13.0 1.13
Vision disordersb 8.7 1.26
Hearing loss, adult onset 4.3 0.92
Cardiovascular diseases 3.3 0.82
Respiratory diseases 4.2 0.72
Musculoskeletal diseases 4.6 1.18
Other non-communicable diseases 8.9 0.90
III. Injuries 11.7 0.66
Unintentional injuries 9.7 0.75
Intentional injuries 2.0 0.32
a Developing countries includes all countries except for European countries, former Soviet countries, Canada, USA, Cuba, Japan, Australia, New 
Zealand, Brunei Darussalam, Singapore.
b Vision disorders includes vision loss due to glaucoma, cataracts, macular degeneration and other age-related vision loss.BMC Public Health 2004, 4:66 http://www.biomedcentral.com/1471-2458/4/66
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(corresponding to a health state with mobility and self-
care limitations and where the person cannot carry out
usual daily activities) was assumed for the institutional-
ized population. Sensitivity analyses showed that the
resulting HALE estimates were not sensitive to the choice
of this disability weight within a plausible range of
variation.
Calculation of posterior severity-weighted prevalences
Because there is potential measurement error in severity-
weighted health state prevalences derived from both
household surveys and epidemiological estimates, poste-
rior estimates of prevalence for the survey countries were
calculated as weighted averages of the GBD-based preva-
lences and the survey prevalences [23]. The relationship
between the GBD-based prevalences and the posterior
prevalences was estimated for the survey countries using
ordinary least squares regression and the results used to
adjust the GBD 2000-based prevalences for the non-sur-
vey countries. This ensured that the use of the survey data
did not introduce a prevalence differential between survey
and non-survey countries, and allowed the survey evi-
dence to be indirectly taken into account in making the
best possible prevalence estimates for non-survey
countries.
Calculation of HALE and uncertainty intervals
HALE was calculated using Sullivan's method [32] based
on abridged country life tables and the posterior severity-
weighted prevalences. Uncertainty ranges for HALE esti-
mates were estimated using Monte Carlo simulation tech-
niques to quantify the uncertainty in life expectancy
projections, in GBD estimates for prevalence and disabil-
ity severity, and in the survey-based prevalence estimates
[23].
Apart from ongoing revisions to the GBD analyses of epi-
demiological information on diseases and injuries, the
implementation of improved methods for dealing with
comorbidity has resulted in a reduction in estimated pro-
portion of healthy years of life lost at older ages compared
to previous years.
Improvements in methods used for the analysis of the
MCSS survey data and in the adjustment of total YLD rates
for dependent comorbidity have resulted in improved
estimates of the severity-adjusted prevalence of health
states and a reduction in the uncertainty associated with
these estimates. For these reasons, HALE estimates for
2002 are not directly comparable with those for 2000 and
2001 published in the World Health Report 2002 [33].
Results
The survey data identified considerable variability in the
use of question response categories to describe the same
level on a particular health domain and a systematic ten-
dency for people in countries with higher income per cap-
ita to use more severe response categories in rating a given
anchoring vignette. Thus the self-reported prevalence of
problems for a health domain in a country may be quite
different from the prevalence of problems after adjust-
ment for these response category cut-point shifts. In
France, for example, 70% of survey respondents gave self-
report responses of mild or greater problems on the ques-
tion for the affect domain (anxiety and depression),
whereas the standardized (vignette-adjusted) prevalence
at all levels higher than "none" was only 33% for France.
In contrast, for some countries such as Egypt, the self-
report and standardized prevalences were almost the same
at around 38%.
Figure 2 shows average HALE at birth for 192 countries,
plotted against income per capita (Gross Domestic Prod-
uct measured in international dollars using purchasing
power parity conversion rates) on a logarithmic scale. The
error bars show estimated 95% uncertainty ranges for
HALE at birth. Country-specific estimates of male and
female HALE and total life expectancy at birth and at age
60, together with 95% uncertainty ranges, are provided in
the World Health Report 2004 [20].
Japanese women led the world with an estimated average
HALE at birth of 77.7 years in the year 2002, 7.5 years
lower than total life expectancy at birth. HALE at birth for
Japanese males was 72.3 years, 5.4 years lower than for
females. This male-female gap in HALE was narrower than
that for total life expectancy at birth (6.9 years). After
Japan, in second to seventh places, were San Marino, Swe-
den, Switzerland, Monaco, Iceland and Italy, with HALE
at birth (males and females combined) in the range 72.7
to 73.4 years, followed by Australia and a number of other
industrialized countries of Western Europe. There was a
considerable range of uncertainty in the ranks for coun-
tries other than Japan, with typical 95% uncertainty
ranges for HALE of around 0.5 to 2 years for developed
countries. Keeping these uncertainty intervals in mind,
Canada was in 11th place (72.0 years) and the USA in
29th place (69.3 years).
Other countries with reasonably high HALE in the Ameri-
cas included Argentina (65.3 years), Chile (67.3 years),
Costa Rica (67.2 years), Cuba (68.3 years), Mexico (65.4
years), Panama (66.2 years) and Uruguay (66.2 years).
Brazil was split, with a high HALE in its southern half, and
a lower one in the north. The total average was a relatively
low 59.8 years, at 57.2 for males and 62.4 for females.
Overall, global HALE at birth in 2002 for males and
females combined was 57.7 years, 7.5 years lower than
total life expectancy at birth (Figure 3). In other words,BMC Public Health 2004, 4:66 http://www.biomedcentral.com/1471-2458/4/66
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poor health resulted in a loss of nearly 8 years of healthy
life, on average globally. Global HALE at birth for females
was only 2.7 years greater than that for males. In compar-
ison, female life expectancy at birth was 4.2 years higher
than that for males. Global HALE at age 60 was 12.7 years
and 14.7 years for males and females respectively; 4.3
years lower than total life expectancy at age 60 for males
and 5.3 years lower for females.
HALE at birth ranged from a low of 40 years for African
males to over 70 years for females in the low mortality
regions of Western Europe, North America and the Pacific
(Japan, Australia, New Zealand). This reflects an almost 2-
fold difference in HALE between major regional popula-
tions of the world (Figure 3). The equivalent "lost"
healthy years (total life expectancy minus HALE) ranged
from 15% of total life expectancy at birth in Africa to 8–
9% in the European region and the Western Pacific region.
The sex gap was highest for Eastern Europe and lowest in
North Africa and the Middle East.
There was a similar almost two-fold variation in HALE at
age 60 across the regions of the world, ranging from 19
years for women in low-mortality countries to around 10
years for men and women in sub-Saharan Africa. Males
lost more healthy years of life at age 60 than females only
in China and South East Asia, where life expectancy gaps
at age 60 were also low compared with the more than 5-
year gap in Japan (due to high female life expectancy) and
Healthy life expectancy at birth versus Gross Domestic Product (GDP) per capita, 192 WHO Member States Figure 2
Healthy life expectancy at birth versus Gross Domestic Product (GDP) per capita, 192 WHO Member States. 
Healthy life expectancy at birth in 2002, together with 95% uncertainty ranges, versus Gross Domestic Product (GDP) per cap-
ita for 2001 in international dollars (purchasing power parity conversion), 192 WHO Member States
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in Eastern Europe (due to high adult male mortality
rates).
There was an enormous difference between the world's
highest HALE at birth of 77.7 years (for females in Japan)
and the lowest of 27.2 years (for males in Sierra Leone) in
2002. In Sierra Leone, people both lived shorter lives
(male life expectancy at birth was estimated at 32.4 years),
and had higher levels of disease and disability at all ages.
The probability of a male child dying before his 5th birth-
day was 33% in Sierra Leone, compared with less than
0.5% in Japan.
The low levels of HALE in sub-Saharan Africa reflect the
additional impact of the HIV-AIDS epidemic, as well as
war and conflict in some countries such as Sierra Leone.
AIDS is now the leading cause of death in Sub-Saharan
Africa, far surpassing the traditional deadly diseases of
malaria, tuberculosis, pneumonia and diarrhoeal disease.
AIDS killed 2.1 million Africans in 2002, versus 300,000
AIDS deaths in 1990 [20,34].
In Russia, HALE at birth was 64.1 for females, 4 years
below the European average, but just 52.8 years for males,
9.4 years below the European average. This was one of the
widest sex gaps in the world and reflects the sharp increase
in adult male mortality in the 1990s. The most common
explanation is the high incidence of male alcohol abuse,
which led to high rates of accidents, violence and cardio-
vascular disease. From 1991 to 1994, the risk of premature
Life expectancy (LE), healthy life expectancy (HALE), and lost healthy years as per cent of total LE (LHE%), at birth and at age  60, by sex and region, 2002 Figure 3
Life expectancy (LE), healthy life expectancy (HALE), and lost healthy years as per cent of total LE (LHE%), at birth and at age 
60, by sex and region, 2002.
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death increased by 50% for Russian males [35]. Between
1994 and 1998, life expectancy improved for males, but
has declined significantly again in the last 3 years [35-37].
Overall, HALE at birth for males in Russia and other
former Soviet countries was 16 years lower than the aver-
age for males in Western Europe; the difference for
females was lower at 9 years. Other Eastern European
countries such as Ukraine and Belarus also had large gaps
between male and female HALE at birth, as did Colombia,
where male HALE at birth was nearly 9 years lower than
that for females.
At the other extreme there were 12 countries where female
HALE at birth was lower than male, and an additional 20
countries where it was less than 1 year higher. These
included African countries greatly affected by HIV/AIDS
such as Botswana, Kenya, Tanzania and Zimbabwe, but
also Eastern Mediterranean countries such as Bahrain,
Kuwait, Qatar and the United Arab Emirates, and Asian
countries such as Afghanistan, India, Pakistan and Bang-
ladesh. Also included were Nigeria and Haiti. In most of
these countries, female life expectancy was slightly higher
than male; only in Qatar, Maldives and Bangladesh was
female life expectancy at birth lower than that for males.
However, higher levels of disability and poor health
reduced HALE for females to a greater extent than for
males in these countries. At a broader regional level, sub-
Saharan Africa, the Eastern Mediterranean region, and the
South East Asian region all had female HALE at birth less
than three years higher than male, compared with a
female-male gap of 6 to 7 years in developed countries.
HALE at birth in Afghanistan was estimated at 35.5 years,
the 11th lowest in the world in 2002. There was a large
95% uncertainty range around this estimate, of 27 to 44
years, reflecting the lack of population health information
for that country. More health information was available
for Iraq, where HALE at birth in 2002 was estimated at
50.1 years, with an uncertainty range of 47 to 54 years.
China had a healthy life expectancy well above the global
average, at 64.1 years, 65.2 years for women and 63.1 for
men. Other countries in the Asian region generally had
lower HALE. Improving health in Viet Nam has resulted in
a HALE of 61.3 years, while Thailand has not improved
significantly over the past decade, with a HALE of 60.1
years in 2002. HALE in Myanmar was just 51.7 years at
birth, substantially behind its South East Asian neighbors.
Figure 4 shows the expectation of lost healthy years at
birth (LHE = LE – HALE) versus total life expectancy at
birth for 192 countries. While lower life expectancies are
generally associated with lower HALE, there were large
variations in HALE and in LHE for any given level of life
expectancy. For example, for countries with a life expect-
ancy of 72, HALE varied from 61.1 to 64.6, a non-trivial
variation.
Correspondingly, LHE varied from 7.3 to 11 years, or by
up to 50%. If male and female HALE are considered sepa-
rately, the range of variation increases to 59–66 at total
life expectancy of 72 years. While LHE increases some-
what with increasing life expectancy up to around 70 years
life expectancy, there is a flattening for males and a trend
to decreasing LHE for females in the countries with long-
est life expectancies. Although there are higher preva-
lences of disabling conditions such as dementia and
musculoskeletal disorders in countries with longest life
expectancies, this is offset by lower levels of disability for
diseases such as cardiovascular disease and chronic respi-
ratory diseases where incidence and mortality rates are
also lower.
Discussion and conclusions
As discussed elsewhere, the new methods used in the
WHO Multi-Country Survey Study offer clear evidence
that self-report data on health status are not comparable,
and allow adjustments that improve the comparability of
the resulting health status measures [18]. Building on the
findings from the MCSS, WHO is now undertaking the
World Health Survey in collaboration with Member States
[38]. During 2003 and the first half of 2004, 73 Member
States conducted the World Health Survey, and results
have now all been received by WHO. The World Health
Survey results will contribute to the analysis of healthy life
expectancy in future years.
Despite the fact that people live longer in the richer, more
developed countries, and have greater opportunity to
acquire non-fatal disabilities in older age, disability has a
greater absolute (and relative) impact on healthy life
expectancy in poorer countries. Separating life expectancy
into equivalent years of good health and years lost to sub-
optimal health thus widens rather than narrows the differ-
ence in health status between the rich and the poor
countries.
Richer countries should be much more active in seeking
ways to improve the health of the world's poor. WHO has
been a strong advocate for efforts to increase the resources
available for this purpose, and the recent report of its
Commission of Macro-economics and Health concluded
that the bulk of the global disease burden is the result of a
relatively small set of conditions, each with an existing set
of effective interventions [39]. The main problems are the
funding of these interventions and access of poor popula-
tions to these interventions. The Commission estimated
that the essential interventions to target these problems
could be provided for a cost of around $34 per person per
year.BMC Public Health 2004, 4:66 http://www.biomedcentral.com/1471-2458/4/66
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The World Health Report 2002 included an analysis of
mortality and morbidity attributable to the combined
effects of 20 selected leading risk factors for 14 subregions
of the world [33,40]. Globally 47% of premature mortal-
ity and 39% of total disease burden were attributable to
the joint effects of the 20 selected risk factors. Removing
these risk factors would lead to an estimated gain of 9.3
years (17%) in global HALE. The regional gains were
between 4.4 years (6%) in the developed countries of the
Western Pacific, to 16.0 years (43%) in parts of sub-Saha-
ran Africa [41]. The World Health Report 2002 also ana-
lyzed the cost-effectiveness of a wide range of
interventions to address these risks. For the first time ever,
policy makers were provided not only with a summary
measure of level of population health (HALE), but also
with information on its determinants (diseases, injuries
and major risk factors) and on the gains that could be
achieved through specific intervention packages, along
with an analysis of the potential improvements in healthy
life expectancy for different regions of the world that
could be achieved through reduction or elimination of
exposure to 20 major global risk factors [33].
The regular assessment of levels of population health is a
key input to the public policy process, and comparable
measurement of population health levels creates possibil-
ities of investigating broad determinants at national and
cross-national level. Mortality indicators are not adequate
for this purpose, given the considerable policy interest for
many populations as to whether – and to what extent –
gains in life expectancy have been accompanied by
improvements in non-fatal health status [9,42-45]. The
Lost healthy years at birth (LE – HALE) versus life expectancy at birth, by sex, 192 WHO Member States, 2002 Figure 4
Lost healthy years at birth (LE – HALE) versus life expectancy at birth, by sex, 192 WHO Member States, 2002.
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trend to flattening or decreasing LHE for countries with
longest life expectancies, noted above, provides the first
cross-population comparable evidence that compression
of morbidity may be occurring in low mortality countries,
although this evidence is cross-sectional rather than
longitudinal.
Comparability is fundamental to the use of survey results
for development of evidence for health policy but has
been under-emphasized to date in instrument develop-
ment. We believe that the new methods used in the WHO
Multi-country Household Survey Study and the World
Health Survey have increased the comparability of self-
report data across countries and provide the first steps
towards the consistent and comparable measurement of
population health across the world. Final confirmation
that compression of morbidity is occuring in low mortal-
ity populations awaits longitudinal cross-population
comparable data for specific populations: this is now
achievable.
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